logo

Trillium Therapeutics Inc. (TRIL)



Trade TRIL now with
  Date
  Headline
9/10/2020 10:13:17 PM Trillium Therapeutics Prices Public Offering Of 10 Mln Shares At US$13.00/shr
4/8/2020 7:15:36 AM Trillium Therapeutics Suspends Business Travel And Implements Work-from-home Policy For All Employees Due To COVID-19
3/10/2020 7:19:17 AM Trillium Therapeutics FY Loss Per Share $1.65 Vs Loss $2.35 Last Year
2/7/2020 7:17:32 AM Trillium Therapeutics Names Paul Walker To Board Of Directors
1/7/2020 8:37:23 AM Trillium Provides Update On Its TTI-621 And TTI-622 Clinical Programs
10/22/2019 9:08:56 AM Trillium Therapeutics Plans Corporate Restructuring; Staff To Be Reduced By 40%
10/8/2019 7:02:47 AM Trillium Granted 180-Day Extension By NASDAQ To Regain Compliance With Minimum Bid Price Rule
9/25/2019 7:05:32 AM Trillium Appoints Jan Skvarka As President And CEO
11/14/2018 7:09:15 AM Trillium Therapeutics 9-month Loss Per Share $2.49 Vs Loss $3.77 Last Year
8/8/2018 7:05:42 AM Trillium Therapeutics 6-month Loss Per Share C$1.57 Vs Loss C$2.79 Last Year
6/15/2018 7:04:43 AM Trillium Therapeutics Completes Amendment To SIRPaFc License Agreement
6/14/2018 7:04:49 AM Trillium Therapeutics Begins Dosing In Its Phase 1 Clinical Trial Of TTI-622 Or SIRPaFc-IgG4